Pharmafile Logo
Pharmafocus logo
Advanced Search

Multaq

Showing 15 posts of 16 posts found.

Gilenya picture

Key product launches of 2011

December 19, 2011
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products

 Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …

Feature

Multaq raises risk of death in permanent AF patients

November 16, 2011
Sales and Marketing AF, Multaq, Sanofi

More bad news for Sanofi’s Multaq as new data shows the drug doubles the risk of death in people with …

News
Sanofi's Multaq

Safety concerns prompt Multaq restrictions

September 26, 2011
Sales and Marketing Multaq

The European Medicines Agency has recommended Sanofi’s Multaq be restricted due to ongoing concerns about its safety profile. The drug …

News

Sanofi’s Multaq in the dock

September 7, 2011
Sales and Marketing Multaq, Sanofi

The EMA will later this month decide whether Sanofi’s Multaq can remain on the market after reports emerged of serious …

News
Sanofi's Multaq (dronedarone)

EMA widens safety review of Sanofi’s Multaq

July 12, 2011
Sales and Marketing Multaq, Sanofi

European regulators are to extend their assessment of the risks associated with Sanofi’s atrial fibrillation (AF) medicine Multaq to take …

News

Bayer contraceptive advert breaches Code of Practice

May 27, 2011
Medical Communications ABPI Code of Practice, Bayer, Multaq, Sanofi, Yasmin

Bayer Healthcare has been singled out for “particular censure” by the PMCPA, the body which regulates the ABPI Code of …

News

Companies join forces to promote AF awareness

February 16, 2011
Medical Communications, Sales and Marketing AF, Multaq, Pradaxa, apixaban, atrial fibrillation

Boehringer Ingelheim and Sanofi-Aventis are to co-sponsor the World Heart Federation’s global atrial fibrillation (AF) education campaign. AF AWARE was …

News

Generics force Sanofi into standstill

February 9, 2011
Sales and Marketing 2010 pharma results, Jevtana, Multaq, Sanofi, Sanofi-Aventis, generics

An onslaught of generic competition combined with healthcare cuts in the US and Europe meant Sanofi-Aventis’ revenues were brought to …

News
Sanofi-Aventis' Multaq (dronedarone)

FDA issues Multaq liver warning

January 17, 2011
Sales and Marketing FDA, Multaq, atrial fibrilation, dronedarone

US regulators have warned doctors and patients about the risk of severe liver injury associated with Sanofi-Aventis’ atrial fibrillation (AF) …

News
Multaq tablets

Sanofi’s Multaq in pole position for AF market

September 6, 2010
Sales and Marketing Multaq, Sanofi-Aventis, atrial fibrilation

New European Society of Cardiology guidelines on treating atrial fibrillation (AF) include a recommendation for Sanofi-Aventis’ Multaq. The endorsement is …

News
Multaq

Multaq given limited approval from NICE

August 25, 2010
Medical Communications, Sales and Marketing Multaq, NICE, Sanofi-Aventis, atrial, dronedarone

NICE has given a restricted approval to Sanofi-Aventis’s Multaq as a second line treatment for atrial fibrillation patients. The guidance …

News

NICE reaffirms positive opinion on Multaq

July 19, 2010
Sales and Marketing Multaq, NICE, antiarrhythmic, dronedarone

In its final draft guidance, UK cost-effectiveness body NICE has reaffirmed its previous positive opinion to recommend the limited use …

News

Novel anticoagulants set to lead atrial fibrillation market

July 9, 2010
Sales and Marketing Brinavess, Multaq, Pradaxa, Xarelto, apixaban, atrial fibrilation

Novel anticoagulants set to capture the atrial fibrillation market by 2019, according to a new report. Analysts Decision Resources say …

News

NICE changes its mind on Multaq

March 30, 2010
Sales and Marketing Multaq, NICE, Sanofi-Aventis

NICE has given preliminary approval of Sanofi-Aventis’ Multaq for the management of patients with atrial fibrillation. The decision reverses an …

News

NICE says no to Multaq

January 8, 2010
Sales and Marketing Multaq, NICE, Sanofi

NICE has rejected Sanofi-Aventis’ new anti-blood clot treatment Multaq (dronedarone) for use on the NHS because of its cost. According …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025